Dose caffeinated energy drink is a consideration issue for endurance performance

Positive and Negative Expectations Associated with Coffee and Energy Drinks: Implications for Placebo-Nocebo Research in Sports

BACKGROUND

Nutritional expectations have been shown to influence exercise performance via placebo and nocebo effects. The present study aimed to evaluate performance-enhancement expectations for coffee and energy drinks using the Stanford Expectations of Treatment Scale.

METHODS

A total of 402 participants (48.5% male) with an average exercise history of 4.53 years, engaging in average physical activity 3.91 times per week, were included in the study. Data collection was conducted through the Qualtrics platform.

RESULTS

Participants exhibited significantly higher positive expectations for coffee compared to energy drinks (p = 0.002), whereas negative expectations were more pronounced for energy drinks than for coffee (p < 0.001). Males and individuals engaging in anaerobic exercise expressed more positive expectations for energy drinks than females and those participating in aerobic or mixed exercise regimens. Additionally, high-frequency exercisers (≥4 sessions per week) reported greater positive expectations for both beverages and fewer negative expectations for coffee than low-frequency exercisers (≤3 sessions per week). Correlational analyses revealed weak but significant associations between expectations and variables such as exercise history, frequency, intensity, and age.

CONCLUSIONS

The findings suggest that coffee is perceived as a more effective performance enhancer and exhibits greater placebo-inducing potential than energy drinks, which may elicit stronger nocebo effects. These group-specific perceptions should be considered by trainers, coaches, and researchers when addressing placebo-nocebo mechanisms in the context of sports and exercise.

Does ergogenic effect of caffeine supplementation depend on CYP1A2 genotypes? A systematic review with meta-analysis

BACKGROUND

The ergogenic effects of caffeine intake on exercise performance are well-established, even if differences exist among individuals in response to caffeine intake. The genetic variation of a specific gene, human cytochrome P450 enzyme 1A2 (CYP1A2) (rs762551), may be one reason for this difference. This systematic review and meta-analysis aimed to comprehensively evaluate the influence of CYP1A2 gene types on athletes' exercise performance after caffeine intake.

METHODS

A literature search through 4 databases (Web of Science, PubMed, Scopus, and China National Knowledge Infrastructure) was conducted until March 2023. The effect size was expressed as the weighted mean difference (WMD) by calculating fixed effects meta-analysis if heterogeneity was not significant (I2 ≤ 50% and p ≥ 0.1). Subgroup analyses were performed based on AA and AC/CC genotype of CYP1A2.

RESULTS

The final number of studies meeting the inclusion criteria was 12 (n = 666 participants). The overall analysis showed that the cycling time trial significantly improved after caffeine intake (WMD = -0.48, 95% confidence interval (95%CI): -0.83 to -0.13, p = 0.007). In subgroup analyses, acute caffeine intake improved cycling time trial only in individuals with the A allele (WMD = -0.90, 95%CI: -1.48 to -0.33, p = 0.002), but not the C allele (WMD = -0.08, 95%CI: -0.32 to 0.17, p = 0.53). Caffeine supplementation did not influence the Wingate (WMD = 8.07, 95%CI: -22.04 to 38.18, p = 0.60) or countermovement jump test (CMJ) performance (WMD = 1.17, 95%CI: -0.02 to 2.36, p = 0.05), and these outcomes were not influenced by CYP1A2 genotype.

CONCLUSION

Participants with the CYP1A2 genotype with A allele improved their cycling time trials after caffeine supplementation. However, compared to placebo, acute caffeine supplementation failed to increase the Wingate or CMJ performance, regardless of CYP1A2 genotype.

The Effect of Acute Caffeine Intake on Resistance Training Volume, Prooxidant-Antioxidant Balance and Muscle Damage Markers Following a Session of Full-Body Resistance Exercise in Resistance-Trained Men Habituated to Caffeine

No previous study has analyzed the impact of caffeine intake on prooxidant-antioxidant balance and muscle damage following resistance exercise. The aim of this study was to determine the effect of 3 mg/kg of caffeine on the number of repetitions and the prooxidant-antioxidant balance and muscle damage after a session of full-body resistance exercise. Ten resistance-trained men habituated to caffeine participated in a randomized, crossover and double-blind experiment. Each participant performed two identical resistance training sessions after the intake of 3 mg/kg of caffeine or a placebo. Blood was collected before and 60 min after substance intake, just after exercise, 60 minutes after exercise, and 24 hours after testing to evaluate the activity of antioxidant enzymes (superoxide dismutase, glutathione peroxidase, catalase), non-enzymatic antioxidants (reduced glutathione, uric acid) levels of oxidative stress markers (plasma malondialdehyde) and muscle damage markers (creatine kinase, lactate dehydrogenase). There were no significant differences between placebo and caffeine conditions in the total number of repetitions (180 ± 15 vs 185 ± 14 repetitions, respectively; p = 0.276; Effect size [ES] = 0.34), the total time under tension (757 ± 71 vs 766 ± 56 s, respectively; p = 0.709; ES = 0.14) or the rating of perceived exertion (13.8 ± 2.7 vs 14.7 ± 2.7 a.u., respectively; p = 0.212; ES = 0.32). Reduced glutathione concentration obtained 1 hour after exercise was higher with caffeine than with placebo (p = 0.047), without significant difference between conditions for any other prooxidant-oxidant or muscle damage marker at any time point (p > 0.050 for all). The oral intake of 3 mg/kg of caffeine by resistance-trained men habituated to caffeine did not enhance the number of repetitions during a medium load full-body resistance training session to failure and had a minimal impact on the prooxidant-antioxidant balance and muscle damage. The study was registered prospectively at ClinicalTrials.gov with the following ID: NCT05230303.